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field of surgical uro-oncology, and to define the current and future role of “precision surgery” in the management of genitourinary cancers.
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lsevier Ltd, BASO ~ The Association for Cancer Surgery,allowed better patient selection and more reliable surgical
planning. On the other hand, the implementation of mini-
mally invasive techniques and technologies, such as
robot-assisted laparoscopy surgery and image-guided
surgery, allowed minimizing surgical morbidity. Ultimately,
these advances have translated into a more tailored
approach to the management of urologic cancer patients.
Following the paradigm of “precision medicine”, contem-
porary urologic surgery has entered a technology-driven
era of “precision surgery”, which entails a range of surgical
procedures tailored to combine maximal treatment efficacy
with minimal impact on patient function and health related
quality of life.1 The aim of this non-systematic review is toand the European Society of Surgical Oncology. All rights reserved.
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the field of surgical uro-oncology, and to define the current
and future role of “precision surgery” in the management of
genitourinary cancers, with a focus on prostate, bladder and
kidney cancer.Prostate cancer
Prostate cancer continues to have a high incidence in
most industrialized countries, despite decreasing mortality
rates.2 Standardization in multi-parametric MRI techniques
allowed better identification of clinically significant can-
cers,3 as well as better disease staging.4 Active surveillance
has taken the stage and has been implemented with
different protocols worldwide for very low-risk, low-risk,
and selected intermediate-risk disease.5,6 A better under-
standing of tumor biology and the availability of novel
prognostic and diagnostic tools have significantly changed
the paradigm in the management of this disease. Several
genomic tests e such as Prolaris, Oncotype DX, and
Decipher e are already commercially available, and are
now being used, in addition to traditional clinical nomo-
grams, although their role is yet to be defined.7 Recent
introduction of 3D printing technology might further
facilitate surgical planning (Fig. 1).
After the golden era of laparoscopic prostate surgery,
modern prostate cancer surgery has been mainly driven
by the rapid adoption of robot-assisted laparoscopy radical
prostatectomy (RARP),8,9 which now represents the gold
standard treatment option in most industrialized coun-
tries.10,11 Moreover, the implementation of multi-Figure 1. 3D printed prostate showing anterior T3 tumor close to sphincter (co
London, UK).parametric MRI imaging to prostate biopsy techniques12
(Fig. 2) has paved the way to the concept of “focal
therapy”.13 This paragraph will be focused on these two
main areas of clinical interest.Robotic surgery for prostate cancer
Refinements in RALP technique
One of main advantages of robotic surgery is certainly
represented by the magnification of the surgical field, al-
lowing a better visualization and easier appreciation of
fine anatomical details. Overall, a better understanding of
surgical anatomy of the prostate has translated into recog-
nition of key anatomical structures, and its possible varia-
tions. Thus, the RARP procedure can be regarded as an
individualized operation that can be tailored to the specific
characteristics of the patient and the cancer.14 The
“trifecta” (cancer control, continence, and potency) has
become the standard metrics to assess the outcomes of
RARP,15 as patient reported health related quality of life
is regarded as an important parameter to consider in pros-
tate cancer treatment.16 Therefore, refinements in surgical
technique have been mainly directed towards the preserva-
tion of patient’s functions, namely urinary continence and
sexuality.
Factors contributing to the continence status of men
undergoing prostate cancer surgery have been extensively
investigated. Besides preoperative parameters (such as age,
prostate size, membranous urethral length, and BMI), the
impact of surgical dissection, damage to neurovascular bun-
dles, and postoperative fibrosis have been recognizedurtesy of Prof. Prokar Dasgupta, King’s College London, Guy’s Hospital,
Figure 2. MRI-US fusion transperineal prostate biopsy (courtesy of Prof. Francesco Porpiglia, San Luigi Hospital, University of Turin, Orbassano, Italy).
895R. Autorino et al. / EJSO 43 (2017) 893e908(Fig. 3).17 Several techniques aiming at restoring the disrup-
ted anatomy secondary to the removal of the prostate gland
have been investigated (Table 1).18e30 These techniques are
based on three key concepts: preservation (bladder neck
sparing, puboprostatic ligaments, puboprostatic collar, pubo-
vesical complex, urethral length); reconstruction (posterior
and/or anterior reconstruction) (Fig. 4); reinforcement
(bladder neck plication and/or sling suspension).31 ThisFigure 3. Factors contributing to urinary continhas also resulted in a debate on the use of a standard nomen-
clature e such as the one proposed by the ESUT e to facil-
itate outcome comparisons and surgical education.32
Sexual dysfunction can represent a common clinical issue
in patients undergoing prostate cancer surgery.33 Several fac-
tors contribute to postoperative recovery of erectile function,
including patient characteristics (age, baseline erectile func-
tion, co-morbidities), surgical technique (non-versus uni- orence status post radical prostatectomy.17
Table 1
Overview of surgical techniques aiming at improved continence status
after RALP.
Anatomical
principle
Reference Technique
Preservation Friedlander18 Bladder neck sparing
Lim30 Retzius sparing
Reinforcement Lee24 Bladder neck plication stitch
Bahler22 Small intestinal submucosa bladder
neck sling
Lei19 Selective suture ligation of dorsal
venous complex
Patel20 Periurethral suspension stitch
Nguyen21 Urethral sling fashioned from
autologous vas deferens
Dal Moro27 Complete Reconstruction of the
Posterior Urethral Support (CORPUS)
Reconstruction Propiglia23 Total anatomical reconstruction
Student25 Advanced reconstruction of
vesicourethral support (ARVUS)
Jeong26 1-step posterior reconstruction
Hurtes28 Anterior retropubic suspension
with posterior reconstruction
Coelho29 Modified posterior reconstruction
896 R. Autorino et al. / EJSO 43 (2017) 893e908bi-lateral nerve sparing; extrafascial versus inter- or intra-
fascial), and surgeon factors (surgical volume and skills)34
(Fig. 5). Despite extensive research in the field of prostate
anatomy, controversies remain in regard to the location, distri-
bution and function of periprostatic nerve fibers. Certainly, it
is not possible to reproduce exactly the same dissection in
every patient, and therefore the surgeon has to find for each
case the best balance between an oncologic safe margin and
the anatomical integrity of the nervous system (Fig. 6). As
anatomical knowledge has increased, there has been a shift
from the simplistic dichotomy “non-nerve sparing versus
nerve sparing” or “intra-inter-extra-fascial” towards theFigure 4. Total (posterior and anterior) anatomical reconstruction during robot-a
Luigi Hospital, University of Turin, Orbassano, Italy).concept of “incremental nerve sparing” or “incremental
safety margin”.14 In this regard, grading systems have been
proposed to define the extent of tissue margin on the pros-
tate.10,35,36 Tewari et al. proposed four grades of dissection
by using the veins on the lateral aspect of the prostate as a
vascular landmark.35 Patel and coworkers proposed an inverse
(grade 5 optimal nerve sparing, grade 1 no nerve sparing) five-
grade scale by using the arterial periprostatic vasculature as
landmark and by identifying a “landmark” artery.36
The concept that cautery-free dissection or pinpointed
low-energy cauterization should be implemented when
aiming at nerve preservation is well established.33 In addi-
tion to this, investigators have explored several other tech-
nical refinements that would minimize nerve damage. Some
noted that counter-traction on the neurovascular bundle
(done by either the assistant or the console surgeon) might
translate into neuropraxia and delayed recovery of sexual
function.37 A Retzius-sparing approach pioneered by Boc-
ciardi and coworkers in order to perform the entire proced-
ure through the pouch of Douglas might translate into
higher potency rates.38 The Martini Clinic group described
a safe and effective way of performing intraoperative neu-
rovascular structure-adjacent frozen section examination
(so called “NeuroSAFE”) during RARP.39 More recently,
Patel et al. showed that the placement of dehydrated human
amnion/chorion membrane around the neurovascular
bundle can translate into earlier return of potency.40 Other
technologies are being investigated to facilitate precise
identification of periprostatic nervous structures, such as
fluorescence imaging and confocal laser endomicroscopy.41
RARP: long term oncological data and comparison with
open surgery
More than 15 years have passed since RARP was
first described,42 and mature data are now availablessisted radical prostatectomy (courtesy of Prof. Francesco Porpiglia, San
Figure 5. Factors contributing to potency status post radical prostatectomy.34
897R. Autorino et al. / EJSO 43 (2017) 893e908showing that the procedure is effective in long term
cancer control, even in patients with high-risk disease
(Table 2).43e49
Theoretically, robot-assisted surgery should be the ideal
model to determine the impact and limitations of “surgical
precision” providing better ergonomic for the surgeon,
particularly during reconstructive steps, better vision and
magnification during dissection of the prostate and sur-
rounding anatomical details. Nevertheless, there is still a
debate on “robotic versus open surgery” for prostate cancerFigure 6. Image-guided nerve sparing robot assisted radical prostatectomy (court
Orbassano, Italy).mainly fueled by large population-based data analyses
(Table 3).50e56 Hu et al. reported two large analyses from
the SEER Medicare dataset. They found that RARP is asso-
ciated with lower likelihood of positive surgical margins for
intermediate-risk (15.0% versus 21.0%; OR: 0.66) and
high-risk (15.1% versus 20.6%; OR: 0.70) disease, as
well as less use of additional cancer therapy (at 24 months
OR: 0.67).50 Moreover, they found that RARP is associated
with an equivalent risk of all cause (HR 0.85) and cancer
specific (HR 0.85) mortality.55esy of Prof. Francesco Porpiglia, San Luigi Hospital, University of Turin,
Table 2
Oncological outcomes of RALP: overview long term data.
Reference Institution Pts, n Time period Median
follow-up,
months
BRFS CRFS CSS
Sooriakumaran43 Karolinska University, Stockholm, Sweden 944 2002e06 75.6 82.6% @ 9 yrs e e
Abdollah44 Henry Ford Hospital, Detroit, MI, USA;
Martini Clinic, Hamburg, Germany;
San Raffaele University, Milan, Italy
1100* 2002e13 49 50% @ 10 yrs 87% @ 10 yrs e
Diaz45 Henry Ford Hospital, Detroit, MI, USA 483 2001e03 120 73.1% @ 10 yrs e 98.8 @ 10 yrs
Abdel Raheem46 Yonsei University, Seoul, Korea 800 2005e10 64 76.4 @ 5 yrs 94.6% @ 5 yrs 96.7% @ 5 yrs
Suardi47 OLV Robotic Surgery Institute,
Aalst, Belgium
184 e 67.5 81% @ 7 yrs e e
Billia48 Guy’s and St. Thomas’ Hospitals,
London, UK
175 e e 95.4% @ 5 yrs e 98.3% @ 5 yrs
Liss49 University of CaliforniaeIrvine,
Orange, CA, USA
289 2002e06 e 84.9% @ 5 yrs e 99% @ 5 yrs
BRFS ¼ Biochemical recurrence free survival; CRFS ¼ Clinical recurrence free survival; MFS *D’Amico high risk only.
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data Leow et al. looked at outcomes and costs of over
600,000 radical prostatectomies done in the USA over a
10-year period.52 First of all, they found utilization of
robotic surgery rapidly increased from 1.8% in 2003 to
85% in 2013 (p < 0.001). Moreover, RARP patients were
less likely to experience complications ([OR 0.68,Table 3
Robotic versus open radical prostatectomy: high quality comparative studies to
Reference Study design Country No. of patients
Hu50 Retrospective observational
study from SEER database
USA 5556 RALP
versus 7878 ORP
Haglind51 Prospective, controlled, non
randomized multicenter
(LAPPRO study)
Sweden 1847 RALP
versus 778 ORP
Leow52 Retrospective observational
study from Premier Hospital
database
USA 311,135 RALP
versus 318,458 ORP
Seo53 Systematic review and
meta-analysis
Korea 61 studies
Yaxley54 RCT Australia 157 RALP
versus 151 ORP
Hu55 Retrospective observational
study from SEER database
USA 6430 RALP
versus 9161 ORP
Thompson56 Prospective observational
single surgeon study
Australia 866 RALP
versus 686 ORP
SEER ¼ surveillance epidemiology and end results; LAPPRO ¼ laparoscopic pro
assisted laparoscopic radical prostatectomy; ORP ¼ open radical prostatectomy;
ADT ¼ androgen deprivation therapy; RT ¼ radiation therapy; BCR ¼ biochemic
mortality.p < 0.001) or to receive blood products (OR 0.33,
p ¼ 0.002). While 90-day direct hospital costs were higher
for RARP, costs were no longer significantly different be-
tween open and robotics for the highest-volume surgeons
(104 cases/yr; þ$1990, p ¼ 0.40) and hospitals (318
cases/yr; þ$1225, p ¼ 0.39). Haglind et al. reported a large
prospective controlled nonrandomized trial involving 14date.
Study period Endpoints Main findings
2004e09 SM status; use
of additional
cancer therapy
RALP associated with
improved SM status for
intermediate- and high-risk
disease and less use of post-
prostatectomy ADT and RT
2008e11 UI and EF @
12 months; SM status
RALP modestly beneficial in
preserving EF.
No significant difference
regarding UI or SM
2003e13 Outcomes and costs RALP confers a perioperative
morbidity advantage; costs no
longer significantly different
when highest-volume
surgeons and hospitals
e Outcomes RALP better risk of UI, EF,
and complications. SM and
BCR rates comparable
2010e14 UI and EF @ 6
and 12 weeks
Similar UI and EF outcomes
2003e12 ACM, PCSM and
use of additional
cancer therapy
RALP with less use of
additional postoperative
cancer therapies, and
equivalent ACM and PCSM
2006e12 Quality of life
and SM
After a long learning curve,
RALP has superior sexual,
early urinary, and pT2 SM
outcomes
statectomy robot open; RCT ¼ randomized controlled trial; RALP ¼ robot-
SM ¼ surgical margin; UI ¼ urinary incontinence; EF ¼ erectile function;
al recurrence; ACM ¼ all cause mortality; PCSM ¼ prostate cancer specific
Table 4
Ongoing trials on radical surgical treatment of primary tumor in patients with oligometastatic prostate cancer (www.clinicaltrials.gov).
Institution Name of trial Study design Treatment groups Study sample Primary endpoint Expected
to be reported
MD Anderson Cancer Center
(USA)
e RCT BST versus BST þ RP or RT 120 PFS 2018
Oxford University (UK) TRoMbone RCT ADT versus ADT þ RP 50 Feasibility to
randomize
@ 6 months
2018
Martini Clinic (Germany) g-RAMPP RCT ADT versus ADT þ RP 452 CSS 2025
University of Vienna (Austria) e Prospective
phase IeII
RP 50 90-day
complication rate
2021
RCT ¼ randomized clinical trial; PFS ¼ progression-free survival; CSS ¼ cancer specific survival; BST ¼ best systemic therapy; RP ¼ radical prostatec-
tomy; RT ¼ radiation therapy; ADT ¼ androgen deprivation therapy.
899R. Autorino et al. / EJSO 43 (2017) 893e908Centers from Sweden and comparing robotic (n ¼ 1847) to
open (n ¼ 778) radical prostatectomy.51 They could only
find a modest benefit of robotic surgery for preservation of
erectile function, whereas no difference was found in terms
of continence and positive margin rates. Seo et al. reported
the latest systematic review and meta-analysis of studies
comparing open to robotic surgery for prostate cancer.53
They included 61 studies, and confirmed that RARP carries
a lower risk of complications and urinary incontinence, as
well as higher potency rate, whereas positive margin rates
and recurrence free survival were similar. However, the
authors pointed out the low quality of available studies.
Moreover, they did not include the only available ran-
domized controlled trial, which was recently reported by
Yaxley et al. from the Royal Brisbane and Women’s Hospi-
tal (Brisbane, Australia).54 Primary outcomes were urinary
function and sexual function at 6 weeks, 12 weeks, and 24
months and oncological outcome (positive surgical margin
status and biochemical and imaging evidence of progres-
sion at 24 months). The trial was powered to assess
health-related and domain-specific quality of life outcomes
over 24 months. In this preliminary report the authors
reported the early outcomes at 6 weeks and 12 weeks.
Overall, 151 in the radical retropubic prostatectomy group
proceeded to surgery and 157 in the RARP group. Urinary
function scores did not differ significantly between the
radical retropubic prostatectomy group and RARP group
at 6 weeks post-surgery (p ¼ 0.09) or 12 weeks post-
surgery (p ¼ 0.48). Sexual function scores also did not
differ significantly between the groups at 6 weeks
(p ¼ 0.45) or 12 weeks (p ¼ 0.18) post-surgery. There
was also no difference for proportion of positive surgical
margins between the two groups (10% for open and 15%
for robotic, p ¼ 0.21), as well as for postoperative compli-
cations (9% for open and 4% for robotic, p ¼ 0.052).
Obviously, these findings generated different interpreta-
tions. As there was no difference between the two tech-
nique one might argue that the application of robotic
surgery does not provide any benefit to the patient. On
the other hand, by taking a close look, few important points
need to be pointed out. The two surgeons involved in the
trial had a very different surgical experience as one hadperformed about 200 robotic cases (in 2 years) and the
other over 1500 open cases (in 15 years) at the start of
the trial. Thus, it can be argued that robotic surgery allowed
the less experienced surgeon to achieve equal outcomes
significantly faster. This concept is also supported by the
findings from the study by Thompson et al., who analyzed
over 1550 cases to determine whether a well established
open surgeon (over 3000 cases) could achieve better out-
comes by switching to robotics. They found that, after a
learning curve, the surgeon could indeed improve, espe-
cially their functional outcomes.56
New frontiers of prostate cancer surgery: oligometa-
static cancer and nodal recurrent cancer
Over the past years, oligometastatic cancer e clinically
defined as disease with up to five extra-pelvic lesion e as
has been recognized as separate clinical entity from advanced
cancer, mostly thanks to the implementation of functional
imaging.57 A growing body of evidence seems to support
the hypothesis that a radical treatment to their primary tumor,
alongside “metastasis-directed therapy”, might be beneficial
for patients with oligometastatic cancer. These have been
suggested by recent large population-based studies, from
both USA58 and Europe.59 Gandaglia et al. reported on the
outcomes of a selected cohort of 11 patients with oligometa-
static disease treated with radical prostatectomy and
extended pelvic lymph node dissection. Adjuvant androgen
deprivation therapy was administered to 10 patients (91%).
The 7-yr clinical progression-free and cancer specific sur-
vival rates were 45% and 82%, respectively.60 Ongoing
trials whose findings will be available within the next few
years, will better define the best approach for oligometastatic
prostate cancer (Table 4) (www.clinicaltrials.gov).
Salvage lymph node dissection has been recently
proposed as possible treatment option in selected prostate
cancer patients with disease recurrence limited to regional
and/or retroperitoneal nodes.61 This novel therapeutic
approach has become available due to recent advances in
the field of nuclear medicine imaging modalities, such as
PET/CT and PET/MRI.62 Several centers have reported
initial series with encouraging results (Table 5),63e67 but
further clinical investigation is required.
Table 5
Reported series on salvage lymph node dissection in recurrent prostate cancer.
Reference No. of
patients
Imaging modality Surgical
technique
Follow-up Outcomes
Suardi63 59 11C-choline PET/CT scan Open 81.8 mo^ BR: 59.3%
8-yr BCR-free survival in patients with BR: 23%
8-yr CR- and CSM-free survival: 38% and 81%
Osmonov64 45 11C-choline PET/CT 42.7 mo* BCR-free survival: 73.3%; CSS: 91.7%; OS: 80.6%
Winter65 13 11C-choline PET/CT 72 mo^ BR: 91%; Complete biochemical remission: 30%
Montorsi66 16 11C-choline or (68)Ga-PSMA PET/CT Robotic 40 days BR: 33.3%
de-Castro Abreu67 10 Carbon-11 acetate PET/CT imaging 2 mo In patients with positive nodes, median PSA
decreased by 83%
BR ¼ biochemical response; BCR ¼ biochemical recurrence; CR ¼ clinical recurrence; CSM ¼ cancer specific mortality; CSS ¼ cancer specific survival;
OS ¼ overall survival;^¼ median; * ¼ mean.
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sive tissue-preserving treatment strategy for localized pros-
tate cancer.68 The rationale supporting this strategy is
mainly based on the concept of “index lesion”, and on
the increased ability to detect this lesion (and to rule out
high-risk lesions) thanks to the standardization of MRI
imaging-based biopsy techniques.69
In a recent systematic review, Valerio et al. analyzed 37
studies including over 3200 patients in order to summarize
the current evidence on different modalities of focal therapy
for prostate cancer.70 Overall, seven different sources of en-
ergy have been tested, with some of them (high-intensity
focused ultrasound [HIFU], cryotherapy, photodynamic
therapy [PDT], brachytherapy) studied on larger samples,
some others (laser interstitial thermotherapy [LITT], irre-
versible electroporation [IRE]) still in a more preliminary
stage of assessment (Table 6). Among these, HIFU and
cryotherapy are those that have been mostly implemented
in clinical practice. However, evidence supporting the use
of newer technologies, such as PDT, in low-risk cancer is
being reported in large scale phase III studies.71
Bladder cancer
Urothelial bladder cancer represents a complex
disease with a high prevalence, and high morbidity and
mortality if not optimally treated.72 Traditionally, its bestTable 6
Focal therapy for prostate cancer: current evidence.70
Technique No. of
studies
No. of
patients
Median follow-up,
months
Overall
survival, %
HIFU 13 346 12 100
Cryotherapy 11 1950 26 100
PDT 3 116 6 100
LITT 4 50 4.5 100
Brachytherapy 2 339 61 na
IRE 3 66 6 100
HIFU ¼ high-intensity focused ultrasound; PDT ¼ photodynamic therapy; LIT
na ¼ not available.surgical treatment depends on the stage of the disease:
for non-muscle-invasive cancer, transurethral resection
(TURB) followed by induction and maintenance immuno-
therapy with intravesical BCG or chemotherapy represents
the current standard73; for muscle-invasive cancer, radical
cystectomy with neoadjuvant chemotherapy offers the
best chance for cure, whereas in selected patients
bladder-sparing modalities, consisting of transurethral
resection with chemo-radiation, can be considered.74
Over the past decade, two major areas of research in the
field of bladder surgery have been investigated, that of new
optimal imaging technologies for non-muscle-invasive dis-
ease, and that of robotic surgery for the management of
muscle-invasive disease.Innovations in optical imaging technologyPrecision surgery for bladder cancer patients mostly
relies on initial diagnostic endoscopic accuracy. The current
standard “white light cystoscopy” presents significant short-
comings, including suboptimal detection of flat lesion
(carcinoma in situ), inaccurate tumor delineation to facili-
tate complete resection, challenging differential diagnosis
with inflammatory lesions, and difficult determination of
grade and stage. Therefore, novel technologies have been
developed and implemented to aid the surgeon during
endoscopic management of bladder cancer.75 These can be
broadly categorized in macroscopic (photodynamic diag-
nosis [PDD]; narrow band imaging [NBI]; post-processingDisease specific
survival, %
Adverse event
rate, %
Continence
rate, %
Potency
rate, %
100 1.5 100 88.6
100 2.5 100 81.5
100 10.6 na 88.4
100 0 100 100
99.9 na 95.2 na
100 0 100 100
T ¼ laser interstitial thermotherapy; IRE ¼ Irreversible electroporation;
901R. Autorino et al. / EJSO 43 (2017) 893e908of the endoscopic image [SPIES]) and microscopic
(confocal laser endomicroscopy [CLE]; optical coherence
tomography [OCT]) ones.
PDD is also known as “fluorescence” or “blue light”
cystoscopy. It requires preoperative intravesical administra-
tion of a contrast agent (a protoporphyrin analogue), a blue
light (380e480 nm) source, and specialized lens and cam-
era. PDD has been implemented in Europe for the past two
decades using 5-aminolevulinic acid (5-ALA). Its deriva-
tive hexaminolevulinate (HAL; Hexvix/Cysview) has
become more recently available and it was approved by
the FDA in 2010 on the basis of a phase III trial showing
a 16% reduction in rate of recurrence at 9 months versus
white light cystoscopy.76 PDD seems to provide a better
detection of both papillary and flat appearing CIS lesions.
Burger et al. reported a meta-analysis of raw data from pro-
spective studies on 1345 patients, and they found that PDD
detected significantly more Ta tumors (14.7%) and CIS le-
sions (40.8%) than standard cystoscopy. Moreover, about
25% patients with at least one additional Ta/T1 tumor
was identified when using PDD, and in 26.7% of patients,
CIS was detected only by PDD. Overall, recurrence rates
up to 12 months were significantly lower with PDD
(34.5% versus 45.4%).77 However, a prospective random-
ized multicenter study found no significant difference in
tumor recurrence and progression when using PDD.78 In
another pooled analysis of 3 phase III multicenter trials
detection rate for CIS was 87% with PDD and 75% for
standard cystoscopy.79 However, no data to date have sug-
gested that use of PDD translates into a reduction in disease
progression. False positive can be regarded as a drawback
of the technology, as they occur in 10e12% of patients.76
NBI is a technology that filters out the red spectrum of
white light resulting in blue and green spectra that are pref-
erentially absorbed by hemoglobin, thus enhancing the
mucosal and sub-mucosal vasculature without need of any
dye. This technology has been incorporated into rigid and
flexible scopes, which carry a toggling functionality
between white light and NBI, allowing real time assessment
of suspicious areas. The first study on NBI was reported by
Herr and Donat in 2008, suggesting a better detection rate
than white light cystoscopy.80 Since then, multiple other
series have been reported. A recent meta-analysis of 8
studies including 1022 patients showed the sensitivity and
specificity of NBI and white light cystoscopy to be 94%
versus 85% and 85% versus 87%, respectively.81 Another
recent meta-analysis demonstrated that NBI-TURB can
reduce the risk of recurrence at 3 months, 1 year and 2
years.82 The Clinical Research Office of the Endourological
Society (CROES) conducted a prospective randomized
single-blind multicentre study comparing NBI and white
light in patients with primary non-muscle-invasive bladder
cancer. Overall, 965 patients were enrolled in the study
(481 underwent eassisted TURB and 484 received
NBI-assisted TURB). In patients at low risk for disease
recurrence, recurrence rates at 12 months were significantlylower in the NBI group (5.6% versus 27.3%; p ¼ 0.002).83
Similar results can be obtained by the use of SPIES, as the
image quality and definition is similar to NBI.41
While PDD, NBI and SPIES have been clinically imple-
mented on a large scale, other technologies such as CLE
and OCT are still considered investigational. CLE is a tech-
nology that allows real time microscopy of the mucosa,
and, after being primarily used in gastroenterology, it has
been recently approved for clinical use in the urinary tract
as micro-endoscopy probes (up to 2.6 mm in diameter)
passing through the channel of a standard rigid cystoscope
are now available.84 Fluorescein is used as contrast agent to
be administered intravesically or intravenously. Pioneer
work by Sonn et al. showed that CLE is feasible and it
can differentiate normal urothelium from bladder cancer.85
Clinical data remain limited and further investigation is
awaited. OCT is another real time high-resolution imaging
technology that provides cross sectional images of biologic
tissues by relying on information gathered by reflected
energy (similarly to B mode ultrasound). Current technol-
ogy uses a 2.7 mm diameter probe that can be passed
through the cystoscope allowing visualization of the
different layers of the bladder wall and to distinguish
benign from malignant characteristics. Few studies have as-
sessed the classification of OCT-assisted cystoscopy of
bladder lesions as benign or malignant with a sensitivity
of 84e100% and a specificity of 65e89%.86 Moreover,
another study found a 90% positive predictive value for
tumor invasion into the lamina propria.87 Also for OCT,
clinical studies are going and further results awaited.Sexual and organ preserving approaches for radical
cystectomy (RC)Open RC with pelvic lymph node dissection still repre-
sents the gold standard treatment for non-metastatic
muscle-invasive and selected high-risk non-muscle-invasive
bladder cancer.88 With better understanding of neuro-
functional anatomy, sexual-preserving RC techniques
have been developed over the years in order to achieve
superior functional outcomes, in both male and female
patients with bladder cancer89 (Table 7). Long term data
on “prostate sparing” RC have shown that this can be an
oncologically safe procedure with excellent functional
results in a subset of carefully selected patients.90 “Seminal
vesicle” cystoprostatectomy also resulted in a high
probability of preserving potency, without putting patients
at unnecessary risk.91 “Nerve sparing” radical cystoprosta-
tectomy also showed to not compromise cancer control
while providing improved postoperative quality of
life.92,93 In female patients, genital sparing cystectomy
(with preservation of the uterus, vagina and ovaries) is
feasible in selected women, and it can provide good func-
tional outcome, better sexual function, and favorable onco-
logical outcome.94 A “nerve sparing” technique in female
patients has also been obtained by avoiding damage to
Table 7
Sexual sparing techniques for radical cystectomy: summary of functional and oncological outcomes.90e95
Gender Techniques No. of
studies
No. of
cases
Potency
rate, %
Sexual activity
rate, %
Daytime continence
rate, %
Nighttime continence
rate, %
Local recurrence
rate, %
Male Prostate sparing 12 1098 80e90 Na 88e100 31e98 10
Seminal sparing 79 3
Nerve sparing 29e78 6
Female Genital organ preserving 14 318 na 86.7 70.3 67.2 0e13
Nerve sparing
902 R. Autorino et al. / EJSO 43 (2017) 893e908the proximal urethra and to preserve the autonomic inner-
vation of the rhabdosphincter.95Robotic surgery for bladder cancerSince the first description by Menon et al., in 2003,96
robot-assisted radical cystectomy (RARC) has been adop-
ted in several institutions worldwide.97 Over the last
decade, the debate has been mainly focused on the periop-
erative outcomes of RARC versus the open gold standard
technique. A recent meta-analysis of 19 studies, including
a total of 1779 patients (787 patients in the RARC group
and 992 patients in the open group) suggested that, despite
the longer operative time, patients undergoing RARC might
benefit from lower complication rates, more lymph node
yields, less estimated blood loss, lower need for transfu-
sions, and shorter postoperative length of stay.98 However,
another meta-analysis including only the four available
RCTs comparing open to RARC, with a total of 239 pa-
tients, all with extracorporeal urinary diversion, found no
significant difference between techniques in terms of peri-
operative morbidity, length of stay, positive surgical
margin, lymph node yield. RARC group had significantly
lower estimated blood loss and wound complications, but
again required significantly longer operating time.99 Thus,
further studies are needed to determine the benefit of the
minimally invasive approach for radical cystectomy, and re-
sults from ongoing trials are largely awaited.100 These trials
have to focus on the difficulty of urinary diversion by the
robot-assisted intracorporeal approach as well as on the
oncologic impact of the laparoscopic technique.
In this setting, one of the key-factor is certainly repre-
sented by the urinary diversion, as this is largely recognized
as the surgical step most likely to be associated with occur-
rence of perioperative morbidity. During the early phase of
RARC, extracorporeal urinary diversions were mostly
preferred. Over the past 5 years, the evolution of robotic
surgery has enabled urologic surgeons to perform urinary
diversions intracorporeally.101 Intracorporeal urinary diver-
sion has the potential benefits of a smaller incision, reduced
pain, decreased bowel exposure, and reduced risk of
fluid imbalance. A study by the International Robotic
Cystectomy Consortium found that patients undergoing
intracorporeal diversion after RARC were at a lower risk
of 90-day postoperative complication.102Since radical cystectomy represents a cancer surgery,
oncological outcomes remain a primary concern. Only
few series of minimally invasive radical cystectomy with
long term oncological follow-up have been reported to
date, with encouraging results.103e105 Concerns regarding
the pattern of recurrence after RARC, with one study
showing more frequent extra-pelvic lymph node locations
and peritoneal carcinomatosis in RARC patients compared
to open surgery patients.106 In this regard, studies on lapa-
roscopic series have advocated a potential risk associated
with the use of pneumoperitoneum.107 Nevertheless, a
study on a recent large series of patients who underwent
RARC with intracorporeal urinary diversion at nine
different institutions did not identify unusual recurrence
patterns.108
Kidney cancer
Despite a rising incidence, the mortality of RCC in
developed countries has been stable over the last decade.109
This phenomenon can be explained by the significant ad-
vances in the management of the disease, including refine-
ments in renal biopsy techniques,110 implementation of
active surveillance protocols,111 and adoption of minimally
invasive nephron-sparing surgery procedures.112 This has
resulted into a paradigm shift, which is the idea of tailoring
the treatment to each specific case with the ultimate aim of
achieving the best oncological outcome and the maximal
functional preservation. This process has been facilitated
by the application of new technologies, allowing a better
surgical planning, within the realm of “precision surgery”.Expanding indications of nephron-sparing surgery
and evolving role of robotic partial nephrectomyCurrent clinical practice guidelines recommend partial
nephrectomy (PN) as the gold standard treatment for small
(clinical T1a) renal masses, given the advantages of
nephron-sparing surgery over radical nephrectomy in
terms of renal function preservation.113,114 Emerging
data from centers of excellence as well as from national
databases and meta-analyses have demonstrated oncolog-
ical efficacy for larger masses (cT1b, cT2) with benefits
in terms of renal functional preservation.115e117 On the
other hand, an overarching survival benefit from PN is
Figure 7. Illustration of enucleation versus standard partial nephrectomy for the resection of renal tumors (dashed line ¼ surgical plan of resection).
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analyses suggesting a survival benefit while the sole
randomized clinical (which closed due to poor enrollment
and was thus underpowered) trial failing to demonstrate a
survival benefit for partial nephrectomy despite improved
renal functional outcomes in the partial nephrectomy
arm.118,119
Despite the oncological equivalence to radical nephrec-
tomy and renal functional benefit, PN has been regarded as
a higher risk procedure with increased risk of urinary
fistulae and procedure specific complications. This para-
digm may be shifting however, with the increasing adoption
of the robotic platform. Recent data suggest that robotic
technology may enable surgeons across different practice
settings to perform nephron-sparing surgery more
frequently.120
The robotic approach offers the option of a minimally
invasive PN recapitulating the safety and effectiveness of
the open technique, which can still be regarded as the refer-
ence standard. The standardization of each surgical step has
allowed for optimization of robotic PN procedure.121 With
increasing surgical experience, indications for robotic PN
have significantly expanded to include more demanding
clinical scenarios, such as completely intraparenchymal
tumors,122 hilar tumors,123 and patients with previous ipsi-
lateral nephron-sparing procedure.124
Moreover, current evidence suggests that robotic PN can
translate into better outcomes than conventionallaparoscopic PN. A recent meta-analysis of 25 studies
(including almost 5000 patients) showed that patients
treated with robotics presented larger (WMD 0.17 cm,
p ¼ 0.001) and more complex (WMD 0.59 RENAL score,
p ¼ 0.002) tumors. Nevertheless, robotic surgery was asso-
ciated with a decreased likelihood of conversion (RR 0.36,
p < 0.001), and lower risk of complications (RR 0.84,
p ¼ 0.007) and positive margins (RR 0.53, p < 0.001),
and shorter warm ischemia time (WMD 4.3 min,
p < 0.001).125 Thus, robotics might replace laparoscopy
as the most common minimally invasive approach for PN
whenever the necessary technology is available.126 Howev-
er, in the hands of expert surgeons and with the aid of last
new tools, such as 3D imaging and the ETHOS chair a
more ergonomic position for the surgeon can facilitate the
pure laparoscopy approach.127
From the standpoint of the surgical technique, the recent
debate has been primarily focused on the management of
the renal hilum. The recognized role of warm ischemia
time as a modifiable factor impacting the postoperative
renal functional outcome128 prompted several groups to
explore the feasibility and safety of “zero-ischemia” (off
clamp) and “minimal ischemia” (selective clamping) tech-
niques.129 With the increasing awareness regarding the
preservation of healthy parenchyma as a major determinant
of postoperative renal function,130 another matter of debate
has become the tumor resection technique. While the stan-
dard PN procedure implies the resection of a rim of renal
Table 8
Focal therapy for kidney cancer: overview of available techniques.132e137
Technique Commercial names Mechanism Technique Major
complication
rate, %
Failure
rate, %
FU, months Oncological
outcomes
Current status
CRYO Endocare
(Healthtronics);
Visual-ICE (Galil)
Rapid cooling
leading to cell
necrosis
Perc (CT guided);
Lap (US guided)
0e9.5 1.5e13 20e97.9 RFS: 77%
DFS: 85e97%
CSS: 98.5e100%
Established in
clinical practice
RFA LeVeen (Boston);
Cool-tip (Covidien);
RITA StarBust
(Angiodynamics)
Heat conduction
inducing cellular
death
Perc (CT guided
or MRI guided);
Lap (US guided)
8 2.5e10 27e65.6 RFS: 88e94.2%
DFS: 61.9e90.6%
CSS: 96.8e100%
MWA Acculis
(Angiodynamics);
Evident (Medtronic);
KY2000
(Kangyou Medical)
Kinetic energy
transformed into
heat, leading to
cell death
Perc (CT guided);
Lap (US guided)
2e3 3e4.2% 6e32 RFS: 62e91.3%
DFS: 92.3%
CSS: 85.7e100%
Investigational
IRE Naonoknife
(Angiodynamics)
Electropulses
creating nanoscale
defects in cellular
membrane
Perc (CT or US
guided);
0 10 1e10 RFS: 90
CRYO ¼ cryotherapy; RFA ¼ radiofrequency ablation; MWA ¼ microwave ablation; IRE ¼ irreversible electroporation; FU ¼ follow-up; RFS ¼ recurrence
free survival; DFS ¼ disease free survival; CSS ¼ cancer specific survival.
904 R. Autorino et al. / EJSO 43 (2017) 893e908parenchyma around the tumor, some groups have advocated
“enucleation” techniques131 with the aim of maximizing
preservation of nephrons while effectively removing the
cancer (Fig. 7).Tumor ablation techniquesWith the aim of further minimizing the surgical
morbidity, focal kidney ablation can be offered as an effec-
tive minimally invasive nephron-sparing treatment option.
Several ablative technologies have been investigated to
date; cryoablation and radiofrequency ablation (RFA)
certainly represents the two modalities that have been
most extensively implemented in clinical practice,132
whereas other ablative procedures (microwave ablation,
electroporation) are still investigational133e136 (Table 8).
Overall, probe-ablative therapy provides an attractive
nephron-sparing treatment for small renal masses in older
patients with significant medical co-morbidities who are
poor candidates for standard extirpative surgery. In well
selected patients, kidney ablation can offer several advan-
tages, including improved patient procedural tolerance,
faster recovery, preservation of renal function, and reduc-
tion in the risk of complications. It is likely that outcomes
associated with ablative modalities will improve with
further advances in patient selection, technology and appli-
cation. Emerging data suggest that for both cryoablation
and RFA, patients with non-clear cell and lower grade
histologies may have improved outcomes.137 Patient
counseling about thermal ablation should include a discus-
sion of the risks of local recurrence, and potential need for
re-intervention. Newer energy-ablative modalities have the
potential to become additional nephron-sparing options, but
further investigation is needed.Conclusions
Over the past two decades, the paradigm of uro-
oncological surgery has moved away from the obsolete prin-
ciple of exclusively radical “one-size-fits-all” procedures.
The current surgical therapy of the most common genitouri-
nary cancers aims to combine the maximal oncological
efficacy with the minimal impact on patient’s quality of life
and functionality. A better knowledge of anatomy and cancer
biology coupled with better diagnostic instruments allowed
to improve surgical indications, to optimize surgical plan-
ning, and to tailor the surgical procedure to each specific
patient. The application of novel technologies (robotic sur-
gery, focal therapy, new imaging systems) have facilitated
a minimally invasive approach in most of urologic cancer
patients. We entered an era of “precision surgery”; neverthe-
less, the management of patients with genitourinary cancers
remains suboptimal, and further translational research is
needed to address many unmet needs in this field.
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